AIMD.P AIM4 Ventures

Annovis Bio to Present at the 2020 BIO Investor Forum

Annovis Bio to Present at the 2020 BIO Investor Forum
EN
12/10/2020

Underlying

AIMD.PAIM4 Ventures

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM4 Ventures

 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Annovis to Attend the AAIC 2025 with Four Poster Presentations MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will present four scientific posters highlighting advances of Alzheimer’s c...

June 26, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it received notification (the "Acceptance Letter") from the New York Stock Exchange ("NYSE") that the NYSE has accepted the Company's previously-submitted plan (the "Plan") to regain compliance with the NYSE's continued listi...

June 19, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis to Host Webinar and Live Q&A on June 24, 2025

Annovis to Host Webinar and Live Q&A on June 24, 2025 MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a live webcast where Maria Maccecchini, Ph.D., President and CEO, will provide updates and answer questions from the audience. Webcast Details Date: June 24, 2025Time: 4:30 PM EDTRegistration: During the webcast, Dr. Maccecchini will share...

June 5, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Provides Corporate Updates and Reports First Quarter 2025 Fina...

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and first quarter 2025 financial results. The first quarter was largely dedicated to the initiation of a pivotal Phase 3 clinical trial in early AD, with the first participants entering the study ...

May 13, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Annovis Bio Appoints Hui Liu as Director of Biostatistics MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. “Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence,” said Cheng Fang, Ph.D., Senior Vice ...

April 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch